<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586194</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK10</org_study_id>
    <nct_id>NCT02586194</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study in Patients With Impaired Hepatic Function</brief_title>
  <official_title>Pharmacokinetic Study of ASP015K - Evaluation of Pharmacokinetics in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare and evaluate the pharmacokinetics of ASP015K in&#xD;
      patients with impaired hepatic function and subjects with normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 28, 2015</start_date>
  <completion_date type="Actual">September 27, 2016</completion_date>
  <primary_completion_date type="Actual">September 27, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of ASP015K: AUCinf</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72 hr after dosing</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP015K: Cmax</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metabolites: AUCinf</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of metabolites: Cmax</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by AEs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Supine blood pressure, supine pulse rate and axillary body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
    <description>Hematology, blood biochemistry, and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead ECGs</measure>
    <time_frame>Up to 7 days after the study drug dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: AUClast</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: t1/2</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: tmax</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: CL/F</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ASP015K: Vz/F</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: AUClast</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: t1/2</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of metabolites: tmax</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 60 and 72hr after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Patients With Impaired Hepatic Function</condition>
  <arm_group>
    <arm_group_label>Control (Subjects with normal hepatic function)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>Oral</description>
    <arm_group_label>Control (Subjects with normal hepatic function)</arm_group_label>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject is eligible for the study if all of the following apply:&#xD;
&#xD;
        All subjects:&#xD;
&#xD;
          -  Body weight: ≥40.0 kg and &lt;90.0 kg&#xD;
&#xD;
          -  Body mass index (BMI): ≥17.0 and &lt;30.0 kg/m2&#xD;
&#xD;
          -  Female subject must either:&#xD;
&#xD;
               -  Be post-menopausal or surgically sterile.&#xD;
&#xD;
               -  Agree not to try to become pregnant starting at the time of informed consent&#xD;
                  throughout the study period and for 60 days after the final study drug&#xD;
                  administration if she is of childbearing potential.&#xD;
&#xD;
          -  Agrees to use highly effective contraception&#xD;
&#xD;
          -  Agrees not to donate sperm (for male)/ ova (for female) starting at the time of&#xD;
             informed consent, and throughout the study period and for 90/60 days after the final&#xD;
             study drug administration.&#xD;
&#xD;
          -  Female subject agrees not to breastfeed starting at the time of informed consent, and&#xD;
             throughout the study period and for 60 days after the final study drug administration.&#xD;
&#xD;
          -  Agrees not to participate in a clinical trial, a post-marketing study, or a clinical&#xD;
             study during the period from informed consent to post examination.&#xD;
&#xD;
        A patient with impaired hepatic function:&#xD;
&#xD;
          -  Impaired hepatic function Child-Pugh Score Class A (mild, 5-6 points) or Class B&#xD;
             (moderate, 7-9 points).&#xD;
&#xD;
        A subject with normal hepatic function:&#xD;
&#xD;
          -  Healthy, as judged by the investigator/subinvestigator based on physical examinations&#xD;
             and all tests obtained at screening and during the period from hospital admission to&#xD;
             immediately before study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject will be excluded from participation in this study if any of the following apply:&#xD;
&#xD;
        All subjects:&#xD;
&#xD;
          -  Received or is scheduled to receive any investigational drugs in other clinical&#xD;
             trials, post-marketing studies or clinical research within 120 days before screening&#xD;
             or during the period from screening to the hospital admission.&#xD;
&#xD;
          -  Excessive alcohol or smoking habit.&#xD;
&#xD;
          -  Applies to any of following concerns of tuberculosis:&#xD;
&#xD;
               -  A history of active tuberculosis&#xD;
&#xD;
               -  Abnormalities detected on a chest X-ray test (at screening)&#xD;
&#xD;
               -  Contact with infectious tuberculous patients&#xD;
&#xD;
          -  Applies to any of following concerns except for tuberculosis:&#xD;
&#xD;
               -  Concurrent or previous severe herpes zoster or herpes zoster disseminated&#xD;
&#xD;
               -  More than 1 recurrence of localized herpes zoster&#xD;
&#xD;
               -  Inpatient hospital care for severe infectious disease within 90 days before the&#xD;
                  hospital admission&#xD;
&#xD;
               -  Treatment with intravenous antibiotics within 90 days before the hospital&#xD;
                  admission (prophylactic antibiotics are not applicable)&#xD;
&#xD;
               -  Other than above, a people who has a risk of developing infectious diseases (e.g.&#xD;
                  urethral catheterisation) in judgment of the investigator/subinvestigator&#xD;
&#xD;
          -  Vaccination of live vaccines or live attenuated vaccines within 56 days before the&#xD;
             hospital admission (inactivated vaccines such as influenza vaccine and pneumococcal&#xD;
             vaccine are not applicable).&#xD;
&#xD;
          -  Concurrent or previous drug allergies.&#xD;
&#xD;
          -  A history of clinically serious allergies (serious allergies: Generalised urticaria&#xD;
             which requires hospital admission, allergy which causes anaphylactic shock, etc.).&#xD;
&#xD;
          -  Concurrent or previous cardiac failure NYHA class 3 or 4, long QT syndrome and&#xD;
             congenital short QT syndrome.&#xD;
&#xD;
          -  Development of (an) upper gastrointestinal symptom(s) within 7 days before the&#xD;
             hospital admission.&#xD;
&#xD;
          -  Concurrent or previous lymphatic disease.&#xD;
&#xD;
          -  A history of digestive tract excision, except for a history of appendectomy.&#xD;
&#xD;
          -  Previous use of ASP015K.&#xD;
&#xD;
        A patient with impaired hepatic function:&#xD;
&#xD;
          -  Unable to start washout of concomitant prohibited medications from at least 14 days&#xD;
             prior to the study drug administration.&#xD;
&#xD;
          -  Concurrent uncontrolled hypertension.&#xD;
&#xD;
          -  Clinically significant abnormality detected on standard 12-lead electrocardiogram at&#xD;
             screening or hospital admission.&#xD;
&#xD;
          -  eGFR by the GFR estimating equation for Japanese &lt;45 mL/min/1.73 m2 (the first decimal&#xD;
             place rounded off) at screening.&#xD;
&#xD;
          -  Uncontrolled ascites or pleural effusion observed at screening.&#xD;
&#xD;
          -  Concurrent hepatic encephalopathy Coma Scale II or more at screening.&#xD;
&#xD;
          -  Underwent hepatic transplantation, or underwent hepatectomy within 1 year before&#xD;
             screening.&#xD;
&#xD;
          -  Concurrent or previous drug-induced hepatic disorder.&#xD;
&#xD;
          -  Concurrent acute hepatic disease.&#xD;
&#xD;
          -  With surgically-placed portosystemic shunts including transjugular intrahepatic&#xD;
             portosystemic shunts.&#xD;
&#xD;
          -  Concurrent biliary obstruction.&#xD;
&#xD;
          -  A history of oesophageal haemorrhage or gastric varices haemorrhage within 180 days&#xD;
             before screening.&#xD;
&#xD;
          -  Irregular or acute, and clinically significant LFT values or changes in clinical&#xD;
             symptoms from 30 days before screening to immediately before study drug&#xD;
             administration.&#xD;
&#xD;
          -  Platelet count &lt;4 × 104/μL, or haemoglobin &lt;9 g/dL at screening.&#xD;
&#xD;
          -  Alcohol dependence or unable to remain abstinent during the specified period.&#xD;
&#xD;
          -  Concurrent esophagus or gastric varices which have a high risk of clinically&#xD;
             significant haemorrhage.&#xD;
&#xD;
          -  Concurrent cerebrovascular disorder, serious heart disease, malignant tumour or a&#xD;
             history within 5 years before screening, gastrointestinal disease, urinary disease,&#xD;
             renal disease, endocrine disease, and respiratory disease.&#xD;
&#xD;
        A subject with normal hepatic function:&#xD;
&#xD;
          -  Received or is scheduled to receive medications (including over-the-counter drugs)&#xD;
             within 7 days before the hospital admission.&#xD;
&#xD;
          -  Deviates from any of the normal range of blood pressure, pulse rate, body temperature&#xD;
             and standard 12-lead electrocardiogram at screening or the hospital admission.&#xD;
&#xD;
          -  Meets any of the criteria for laboratory tests at screening or the hospital admission.&#xD;
&#xD;
          -  eGFR by the GFR estimating equation for Japanese &lt;60 mL/min/1.73 m2 (the first decimal&#xD;
             place rounded off) at screening.&#xD;
&#xD;
          -  Concurrent or previous hepatic disease, cerebrovascular disorder, malignant tumor,&#xD;
             heart disease, gastrointestinal disease, except for a history of appendicitis, renal&#xD;
             disease, endocrine disease, respiratory disease, urological disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired hepatic function</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>ASP015K</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peficitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

